Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Monotherapy in the Autism Spectrum Disorders (ASD)
NCT00308074Phase 2Completed
- Sponsor
- Cambridge Health Alliance
- Start
- Feb 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aripiprazole in Autism Spectrum Disorder (ASD), sponsored by Cambridge Health Alliance. Primary endpoints: Clinical Global Impressions-Improvement at 13 weeks and Aberrant Behavior Checklist-Irritability Subscale at 13 weeks. Started Feb 2006; status: completed.
02
Drugs
aripiprazole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00308074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00308074.